Novel Markers and Technology for Better Patient Care

12th October 2015 Rutherford Appleton Laboratory

Precision Medicine Impacting Better Patient CareForeword by Chair

Precision Medicine (“PM”) is a term used to define the field of medicine that uses understandings of large data in a precise manner through more accurate diagnosis, where underlying mechanisms are understood, and which consequently leads to improved treatment outcomes that are predictable and measurable.

This event brings together experts to review better markers and imaging technology to develop PM care pathways. The event is by Medilink UK in partnership with the UK’s premier advanced technology focused Science and Technology Facilities Council (STFC).

At today’s event at STFC’s Rutherford Appleton Laboratory (RAL), the focus will be on how the UK needs to be the best place to develop, and have adopted, PM. This will benefit patients, provide cost-effective solutions for the NHS and healthcare providers and create opportunities for business.

There should be an increased collaborative culture throughout the sector based around shared resources, and systems should be in place for effective data collection, sharing, governance and use across sectors (including NHS,business, academia, regulators and NICE).

It should be quicker and less expensive to develop new drug-diagnosticcombinations and have them licensed, and success should be reflected inincreased UK economic growth.

It should be possible for all NHS patients to be involved in medical research ifthey wish, including through use of patient information and records, in order to inform the next generation of successful therapies.

There should be a smooth reimbursement process for PM therapies anddiagnostics, and an intellectual property (IP) framework that encourages innovation.

The UK health system should have established PM care pathways, andevidence should be available to show that patient outcomes are improved where PM is used.

Adapted from a vision statement - Stratified Medicine in the UK: Vision and Roadmap, 2011

01

STFC SITE RECEPTION08:00 to 10.00 | Manned Registration

AUDITORIUM (PICKAVANCE THEATRE) Session on the needs of NHS, the Industry and how to engage! 10:00 | Welcome address - Science and Technology Facilities Council, Rutherford Appleton Laboratory- ISIS, Prof. Robert McGreevy, Director of ISIS neutron source –Host Welcome Address.10:10 | Chair, Oxford Academic Health Science Network, Nick Scott-Ram, Director of Commercial Development: Precision Medicine – The Development of Better Patient Care Pathways for a More Efficient NHS Service.10:40| GE Healthcare, Ger Brophy, Chief Technical Officer: Precision Medicine –Present and Future, GE Healthcare Perspective.11.00 | STFC-Central Laser Facility, Prof. Stanley Botchway: - Novel Fluorescence Molecular Probes for Bio-Medical Application- Exploring the Time Domain.11.20 I Teas & Coffees11.40 | Medical Research Council, Jonathan Pearce, Translational Programme Manager: - UK Molecular Pathology Landscape and Overcoming barriers to growth.12.00 | ISIS-STFC, Dr Alan Letchford: - Linear accelerator R&D at ISIS-STFC.12.20 | Introductions and Overviews from the Exhibitors (2 min talks)12.40 l Chaired Panel Discussion

EXHIBITION HALL (RAL SPACE VISITORS CENTRE) Exhibitors, B2B and Q&A13:00 | Lunch and Networking 13.40 | Innovative Technology & Service exhibition - Guided Speed-dating for Exhibitors with Industry Leaders with Q&A

AUDITORIUM (PICKAVANCE THEATRE) Session on Industry funding and Investment15:00 | Innovate UK - Penny Wilson, Innovation Platform Leader, Stratified Medicine: - Innovate UK and Precision Medicine.15:20 | Abcodia Ltd – Julie Barnes, Chief Executive Officer: - Capital for Accelerated Success.15:40 | The Knowledge Transfer Network, Ian Tracey, Head of Funding & Finance: -Raising Start Up Capital. 16:00 | Longwall Venture Partners, David Denny, Founder, Partner: - Start Up Challenges & Fundraising. 16.20 | Chair’s Round up and Close - Overview of the day and thanks.

16.30 | Close and Departure – Refreshments available from the Refectory

02

Robert McGreevyDirector ISIS Neutron Source

HOST WELCOME

The ISIS pulsed neutron and muon source at RAL is a world-leading centre for research in the physical and life sciences. From the original vision over 30 years ago, ISIS has become one of the UK’s major scientific achievements. As the world’s leading pulsed neutron and muon source, ISIS has changed the way the world views neutron scattering.

ISIS produces beams of neutrons and muons that allow scientists to study materials at the atomic level using a suite of instruments, often described as ‘super-microscopes’. It supports a national and international community of more than 2000 scientists for research in physics, chemistry, materials science, geology, engineering and biology.

“STFC are very pleased to be supporting this unique event that will aim to highlight the advancement of technologies within the UK in precision medicine and how technology advances at STFC’s RAL facilities have the potential to impact on advances in human health.”

03

Robert has a wealth of experience in managing neutron scattering research centres and has led the ISIS Neutron Source since 2012. Formerly as Deputy Associate Laboratory Director at Oak Ridge National Laboratory and the first coordinator of the highly successful EU NMI3 consortium. He has extensive contacts across European and other international neutron centres.

Nick has over 25 years experience in commercial and business development in the life sciences sector. He has worked in senior management positions in blue chip life science companies including PowderJect Pharmaceuticals. Nick has extensive experience in e-health and personalised medicine. He was awarded the MBE for services to biotechnology in 2001.

Nick will share insight of the needs of the NHS and outline a technology and service evaluation pathway to help guide industry and promotes the AHSN’s objective to improve knowledge exchange and promote health and wealth in a region of 3.3 million people.

Nick Scott-Ram MBEDirector of Commercial DevelopmentOxford Academic Health Science Network

CHAIR & SUPPORTER

The Oxford Academic Health Science Network is one of 15 AHSNs licensed by NHS England to 2018. It brings together the NHS, industry, scientific and academic communities – along with patients and the public. The aim is to bring lasting benefits as best practice is spread quickly and widely across the NHS.

www.OxfordAHSN.org

04

Ger has over twenty years’ experience in the global life sciences and biotechnology industry. He is responsible for the technology and development strategy of the business: from research tools in academia, to bioprocessing tools in drug development and imaging and tools for clinical diagnosis.

Previously he was Head of New Product Development at GE Healthcare Medical Diagnostics encompassing the development of diagnostic technologies, with oversight of discovery and clinical development, and product acquisition and licensing. Before this Ger ran Life Sciences Advanced Systems in Sweden focusing on the commercialisation of tools for drug discovery.

Ger BrophyChief Technical OfficerGE Healthcare Life Science

SPEAKER & SPONSOR

GE Healthcare Life Sciences helps its customers connect biological research to clinical therapy. GE Healthcare supports researchers, pharmaceutical companies and clinicians in the development, manufacturing and use of the next generation of personalised and targeted therapies.

A broad expertise in medical diagnostics, drug discovery, biopharmaceutical manufacturing technologies help GE Healthcare's customers to deliver better care to more people around the world at a lower cost. The “healthymagination” vision for the future drives GE Healthcare to continuously develop innovations focused on reducing costs, increasing access and improving quality in healthcare. Headquartered in Amersham, Bucks, GE Healthcare is a unit of General Electric Company (NYSE: GE)

05

Stanley BotchwaySenior ScientistCentral Laser Facility

SPEAKER & SPONSOR

The Central Laser Facility (CLF) is a Department of the Science and Technology Facilities Council, one of Europe's largest multidisciplinary research organisations supporting scientists and engineers world-wide. The CLF is a partnership between its staff and the large number of members of UK and European universities who use the specialised laser equipment provided to carry out a broad range of experiments in physics, chemistry, biology and medicine.

06

Stan is a visiting professor at Oxford Brookes University and an STFC senior scientist. His primary research focus is multidisciplinary, involving developing laser microscope technologies to study cellular response to localised (sub-micron) damage and repair, investigating proteins involved in cancer induction as well as working with colleagues to develop new fluorescent probes to image cancer cells and tumour environment.

Besides authoring over 80 papers he also holds 5 international patents including new probes for medical imaging. Stan is a member of the Royal Society of Chemistry and Radiation Research Society. Stan has a PhD from the University of Leicester and was a fellow at Harvard Medical School.

Jonathan joined the MRC’s Translational Research Team in 2008. Prior to this Jonathan undertook academic research at Cambridge, Oxford and Toronto, followed by roles in life sciences as a venture capitalist and in strategic consulting. Jonathan manages the Council’s £60 million stratified medicine initiative.

To support this work, he recently undertook a strategic review of molecular pathology, to better understand the opportunities and challenges the field faces in translating basic and clinical findings to patient benefit.

Jonathan Pearce,Translational Programme Manager, Medical Research Council (MRC)

SPEAKER

The MRC supports research across the entire spectrum of medical sciences, in universities and hospitals, in our own units, centres and institutes in the UK, and in our units in Africa. The MRC’s focus on Stratified/Precision Medicine forms a major part of the MRC's research strategy, and seeks to improve our understanding of how to tailor treatments and interventions to the individual needs of people living with a wide range of diseases and conditions. The MRC is coordinating its activities in this area with Innovate UK, the National Institute of Health Research, the UK Health Departments, Cancer Research UK and Arthritis Research UK.

www.mrc.ac.uk07

Alan has worked at the ISIS spallation neutron source for 28 years. He heads a multi-disciplinary team from RAL, Imperial College London, Warwick University, Royal Holloway University of London, Huddersfield University and the ESS Bilbao consortium, Spain, to design, construct and operate a test stand to demonstrate key technologies for the front end of next generation high power proton accelerators.

An engineering background with a strong scientific bent results in being equally at home solving problems in accelerator physics or fixing a MW scale RF amplifier. One of the UK’s most experienced accelerator engineer/physicists whose expertise is routinely called upon to serve on international review committees and advisory boards.

Alan LetchfordHead of linac R&D at ISIS STFC - Science and Technology Facilities Council

SPEAKER & SPONSOR

The ISIS pulsed neutron and muon source at the Rutherford Appleton Laboratory in Oxfordshire is a world-leading centre for research in the physical and life sciences. ISIS produces beams of neutrons and muonsthat allow scientists to study materials at the atomic level using a suite of instruments, often described as ‘super-microscopes’. ISIS supports a national and international community of more than 2000 scientists who use neutrons and muons for research in physics, chemistry, materials science, geology, engineering and biology. As the world’s leading pulsed neutron and muon source, ISIS has changed the way the world views neutron scattering.

www.stfc.ac.uk08

William has been in the computer and communications business since the late 1960s and started Hip Impact Protection 5 years ago to provide proper protection against hip fracture, using modern “reactive” materials. He quickly saw the need for an effective falls detectionand alarm system to complement his hip protectors.

William BeckettCEOHip Impact Protection & Fall Safe

EXHIBITOR

Fall-Safe Assist detects falls with great reliability and virtually no false alarms because it is embedded in the Fall-Safe® hip protector pads, which are located on what is probably the most stable part of the body – the hip. The system communicates with an Android mobile via Bluetooth LE both to send data on the falls and steps preceding them, and to generate alarms using SMS should the faller not immediately rise to their feet, or in the event that the wearer is demonstrating sudden irregularities of gait, or simply has been immobile for an unusually long period. The falls data includes the force, direction, time/date and location of the fall so that after the data has been collated and anonymised it can be analysed to produce predictors of falls, by highlighting common and prevalent characteristics.

These facilities have never been available before so data on falls simply does not exist, hence the ever increasing numbers of fractures, most disastrously of the hip. A report on June 7th in The Lancet showed that falls are the third most common problem, by YLD, in the UK and the second in Central Europe. Clearly a system that has the potential toreduce falls, whilst virtually eliminating hip fractures, meets “an unmet clinical need”. The cost of the device will be <£250, including hip protector pads and several pairs of pants that hold them in place. This compares favourably with >£15,000 for a hip repair operation.

09

As Development Director, Patrick has a dual commercial and technical role at Maddison Product Design. He applies an experience and knowledge gained over 20 years working in the industry, including medical products, FMCG, business electronics and consumer products.

Patrick HallDevelopment DirectorMaddison Product Design

EXHIBITOR

Maddison has a multi-disciplinary team of experienced product designers and engineers, solving complex usability and technical problems, delivering effective products and user interfaces.Maddison design: Disposable diagnostic and drug delivery products; Complex point of care diagnostic and therapeutic devices; Scientific instruments of all kinds - a particular specialism in the solving of challenging physical and virtual patient/user interfaces.Services : depend on the needs of the project and our client. This can include:•Market validation – Are product needs properly understood? What is the competition? What are the barriers to introduction? Is the product commercially viable?•User research – Understanding user needs.•Product design – From concept to full manufacturing specification.•Manufacture and testing of prototypes - Including proof of principle, appearance models and clinical trials units.•Vendor sourcing – Finding appropriate contract manufacturing partners for our clients.Maddison works with: entrepreneurs, start-up companies, technology transfer offices, SMEs and global corporations.

10

Keri is Perspectum's Business Development Manager. She has over 7 years of experience working in the life sciences sector spanning preclinical molecular discovery research and clinical market analysis.

Keri HildickBusiness Development ManagerPerspectum Diagnostics

EXHIBITOR

Perspectum Diagnostics is a recent Oxford University spin-out company founded by physicians, scientists, and engineers. It focuses on the detection and the accurate, quantitative measurement of liver, gallbladder and pancreatic disease, including precancerous and cancerous states. All of these conditions are common and difficult to detect in the early stages. There are currently no non-invasive, quantitative and accurate analysis tools to diagnose them or monitor response to treatment.

Existing methods for assessing liver disease all have fundamental flaws. Perspectum Diagnostics has developed a novel MRI technology, LiverMultiscan™. This replaces liver needle biopsy and is suitable as a screening tool for liver disease. It offers a reliable, safe, quantitative tool for monitoring disease progression and its response to intervention.

LiverMultiScan aims to be as the reference technology for the detection and staging of early liver disease and for quantifying disease progression and response to therapy. It provides detailed information on tissue characteristics as well as architectural changes in a single 15-minute visit with potential savings of over £1000 in cost per patient.

11

Richard received his degree from the University of Birmingham in Physics in 2007. During his studies he focused on several key areas in physics, with a particular interest in astrophysics. As the medical group leader he is working to develop and grow Hamamatsu's UK business in this important sector. Application areas include laboratory diagnostics, point of care diagnostics and medical imaging.

Richard HarveyGroup Leader - Medical Hamamatsu Photonics UK

EXHIBITOR

Hamamatsu Photonics, the world leader in Photonics, are a technology company manufacturing solid state detectors, lasers, MOEMS and electron tube opto-electronic components and systems. The creation, manipulation and detection of light are impacting an increasing number of applications and sectors.

In the medical sector our MPPCs are used for high resolution PET scanners. We are manufacturing X-ray imaging equipment, low light level detectors such as PMTs for fluorescence detection, as well as a range of high end scientific cameras such as the ORCA-Flash4.0, among many other devices.

12

Paul is the Chief Executive of Diasolve & Origin Sciences. He has held senior positions with Lumora (now ERBA), Enigma Diagnostics (Leadman), Roche Diagnostics, Gainor Medical (Alere), Wellcome (GSK).

In other business related activities Paul is a member of NICE’s Diagnostics Advisory Committee, and a member of BIVDA’s board. He has a degree in pharmacology and an MBA from London Business School.

Paul WeinbergerCEODiasolve & Origin Sciences

EXHIBITOR

13

Diasolve was founded to help bring innovative, cost effective diagnostic related products to market. With a highly experienced team Diasolvehas won SBRI phase 1 & 2 awards to assess the opportunity for a more precise approach to fractional flow reserve (FFR) measurement in the cardiac cath lab and develop the FFR infusion micro catheter.

FFR guided intervention has been shown to deliver better outcomes for patients with coronary artery disease than management informed by angiography alone. Furthermore, continuous monitoring of central vascular pressure is a vital tool for keeping patients safe and healthy in the cath lab. Current catheterisation methods require pressure monitoring apparatus to be isolated when fluids are injected and infused, putting the patient at unnecessary risk.

HYPEREM ™IC is the first over-the-wire FFR infusion microcatheter. It is designed to deliver continuous infusion of hyperemic drugs. Continuous intracoronary infusion allows targeted delivery with the aim to provide the cardiologist with greater control, shorten the duration of the procedure and reduce the side effects experienced by patients. Diasolve is now preparing the device for clinical evaluation to support a CE submission, and the team are protecting novel follow-on concepts.

Colin is Emeritus Professor at Newcastle University. He was formerly Head of a large NHS-academic Clinical Biochemistry Department providing test facilities to support regional health provision.

He has had many leadership roles including on large multidisciplinary immunodiagnostic programmes of diverse application including human health, security and environmental monitoring. Colin has also conceived, proved and patented an immunodiagnostic system brought through to SME commercial development, growth and sale whilst at Cambridge.

Colin SelfCEOSelective Antibodies

EXHIBITOR

14

Selective Antibodies Limited (SAL) is a diagnostics company focused on development and production of high performance point-of-need real-time lateral-flow dipsticks to detect small molecules such as therapeutic-drugs, drugs of abuse, hormones, natural and unnatural toxins, chemicals and biological substances.

SAL’s proprietary immunodiagnostic technology are transferable and have been successfully developed for explosives detection and many substances critically important to the environmental and food and drink industries.

SAL’s systems allow positive identification of small molecules –increasing small molecular analyte increases observable signal. This can be readily seen by eye or read with a small hand-held reader.

Applications of the systems are particularly well adapted for point-of need-applications providing rapid quantitative results. These can be delivered by workers needing the simplest possible devices that can be used with minimal training and equipment.

Mark has over 15 years experience in process automation, IoT and software product and business development. He has worked in various industries including telecoms, healthcare, utilities and IT strategy consultancy.

Mark SageBusiness Development DirectoriSeeU Global

EXHIBITOR

iSeeU Global has an enabling medical care platform and associated modular solutions to improve workflow in the medical and social care industry. Through our innovative information flow system, data from various patient contact points can be captured and digitised rapidly (in “real time”) enabling auditable paperless solutions.

This includes our workflow / pathways to standalone / remote monitoring devices and 3rd party sources. From the data collected, actions can be automated, reducing time to respond and significantly improving patient care and feedback loops.

All data is securely stored and made available for legislation reporting. This also enables efficient and effective information exchange between medical providers and the wider care ecosystem.

There are a number of pre-configured modular solutions available (e.g. Care Management platform, Telecare Service Desk, Assessment based e-catalogue, Mobile Lone Worker and Remote monitoring device integration). These solutions can easily be customised to develop new product to product connectivity and services. This offers a rapid and innovative way to deliver a more robust joined up care service.

15

Oliver Blackwell is an Industrial Designer and Founder/CEO of Clever Medical, a Point-of-Care Diagnostic company based in the South West. Oliver has over 10 years experience and specialises in disruptive design and development for several industry verticals, with a focus on medical technologies.

Oliver BlackwellCEOClever Medical

EXHIBITOR

Clever Medical is a young medical company with a strong Industry specialist team with a passion for improving healthcare though the use of Design Thinking. Our first technology is a simple, low cost, highly accurate Point-Of-Care urinalysis test.

Our integrated system consists of a urine collection container and a Diagnosticap. The Diagnosticap is our patented technology, a simple plastic cap that contains urine reagent pads. When clipped together with the urine container, this sealed system is inserted into a simple, digital, desktop urinalysis analyser.

Connecting though a USB cable the result can either be printed or integrated into a patient’s notes. Clever Medical have spent 4 years developing and testing the technology and are looking for clinical and financial support to launch the product in 2016.

16

Penny oversees Innovate UK’s Precision Medicine programme, including infectious diseases, and played an integral part in establishing the Precision Medicine Catapult.

Penny has spent over 25 years in the Diagnostics Industry in a variety of senior technical and strategic roles. In recent years she has focused on point-of-care diagnostics from both a technical and societal perspective and on the challenges of technology integration and adoption.

Penny’s appointments have included Senior Director of Advanced Technology Development for a company developing diagnostic systems for the doctor’s office and Director of Technology Assessment and Acquisition for DPC (now part of Siemens Healthcare). In Global Health Penny has advised the Bill & Melinda GATES Foundation, the Rockefeller Foundation and the African Union.

Penny WilsonInnovation Platform Leader, Stratified MedicineInnovate UK

SPEAKER

17

Innovate UK is the UK's innovation agency and is an executive non-departmental public body, sponsored by the Department for Business, Innovation & Skills. Innovate UK supports companies from concept to commercialisation by connecting organisations, providing funding for the development of commercially viable products and services and supporting SME growth through access to specialists in technology and finance.

The organisation has multiple priority areas and one of its strengths is identifying and supporting innovation at the interface of different areas such as healthcare, data and urban living. In healthcare the organisation has programmes in precision medicine, advanced therapies and independent living.

www.innovateuk.gov.uk

Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company.

Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodiaas an ethical and collaborative organisation.

Julie BarnesChief Executive OfficerAbcodia

SPEAKER

18

Abcodia is a pioneering UK company engaged in the clinical and commercial development of promising tests for the early detection of cancer. The company’s first product to reach the market in 2015 was the ROCA® test, to which Abcodia has an exclusive license for the early detection of ovarian cancer. In addition and in co-operation with University College London, Abcodia is leading technology developments in disease lifecycle utilizing the world’s largest serum biobank and clinical database ever developed, to evaluate potential tests for the early detection of disease, including all major cancers. In 2013 Abcodiaformed an alliance with Cancer Research UK and Cancer Research Technology to discover and validate blood-based biomarkers that may be used in cancer screening.

www.abcodia.com

Ian is responsible for growing and developing the KTN’s strategies for assisting innovative companies by raising finance through lending, grants, or equity based methods. Ian, and the team, work with companies to help them secure the finance they need to grow and create wealth in the UK.

Ian also provides governance to the Venturefest network that supports events around the UK that bring together innovators (with ideas looking for funding), investors (looking for ideas to invest in) and entrepreneurs (putting the ideas and money together to build businesses).

Amongst other activities Ian is elected Secretary General of the CERN based HEPTech organisation, based out of Geneva. HEPTech is the high energy physics technology transfer network.

Ian TraceyHead of Access to Funding & FinanceKnowledge Transfer Network

SPEAKER

19

KTN is the UK’s Innovation Network. They connect people to speed up innovation, solve problems and find markets for new ideas. They help secure the UK’s future by playing to those strengths. The primary role of the KTN is to nurture, develop and scale up innovation within business, connecting you with the wider knowledge economy.Working with large and small companies, government agencies and research organisations, with tech hubs and startups, public funding bodies, VCs and private investors, KTN has built a unique network that helps enterprising people and companies reach the full potential of their innovative capabilities. In the last five years, KTN has helped thousands of businesses secure funding to drive innovation throughout their business cycle to see them through to success.

www.ktn-uk.co.uk

David Denny started as an engineer in CarnaudMetalbox working in a range of roles from R&D to production and project management. David did his MBA at Harvard Business School, after which he worked in business development for the MIT 3D Printing start up Z Corp [sold for $70m]. He has served on the boards of over 15 small companies and is co-founder of Longwall Ventures.

David DennyCo Founder Longwall Ventures

SPEAKER

20

Longwall Venture Partners LLP (‘Longwall’) manages two early stage venture capital funds, the Oxford Technology ECF LP (£30m) and the Longwall Ventures ECF LP (£40m).

Both funds invest in UK early stage science and engineering start-ups. About 40% of the portfolio relate to heathcare and lifescienceinvestments, whilst the balance are predominantly physical science and engineering related.

Longwall is based at the Harwell Science Campus.

www.longwallventures.com

Izhar gained his PhD in Low Temperature Physics and Magnetism before beginning his career as a Project Engineer in 1988 designing high field superconducting magnets and helium cryostats.

He then spent a number of years working for multinational companies in sales and marketing roles as well as managing agents and distributors worldwide. He joined STFC in February 2010.

Izhar Ul-HaqBusiness Development ManagerSTFC - Science and Technology Facilities Council

ORGANISER, EXHIBITOR & SPONSOR

The Science and Technology Facilities Council (STFC) is keeping the UK at the forefront of international science and tackling some of the most significant challenges facing society.

STFC supports the academic and industrial communities by providing large scale science infrastructure and expertise in neutrons, nuclear physics, lasers, astronomy, particle physics, particle accelerators and space science.

www.stfc.ac.uk 21

Life Sciences Healthcare (LSH) is a Life Sciences and Medtech Industry Consultancy with close working relationships with Medilink UK and key national networks and Government Departments. LSH has extensive national and international networks in EMEA, US, South America, India and the Far East. LSH supports high growth technology organisations to achieve enriched innovation pipelines and volume markets earlier - building and realising business value faster in today’s market.

www.lifesciences-healthcare.com

22

Gugs has been at the heart of business growth and strategic development for the UK life sciences and health Industries for 11 years. As CEO of Life Sciences Healthcare Limited he has helped to grow, support and establish over200 start up businesses. This has included activity as the former MD for Medilink South West and in NED and Board roles for several SMEs.

He has worked in senior positions for Government (BIS), SW Regional Development Agency supporting funding into capital developments across UK. He has a Ph.D. from Imperial with 12 years of R&D and innovation development in biotech and molecular marker R&D.

He is also currently working with the Science Technology Facilities Council (STFC) to promote leading technologies at Rutherford Appleton Laboratory through B2B events ideal for UK businesses in the ICT, Advanced Engineering, Medical and Digital industries.

Gugs LushaiCEOLife Sciences Healthcare

ORGANISER & EXHIBITOR

Novel Markers and Technology for Better Patient Care

Aim: “Show and Tell” for break through ideas from innovators and researchers (academic and clinicians) with proof of concepts, prototypes, products and services. This exhibition opportunity has excluded basic distributors or resellers.

Areas of focus include innovation, i.e. the “Push” of: • Evolving predictive and prognostic markers; • Imaging and detection technology and • Software developments that coincide with these.

We have focused on: • Alignment, with relevant healthcare pathways in the NHS and community care; • Improved value to patients; • Improved efficiency over current regimen; • Technology improvements; • Robustness; •Addressing an unmet need; • Equal or reduced cost (with a substantive healthcare economic review of implementation); • Ergonomic fit with existing healthcare pathways (ease of adoption, interoperable etc.).

Applicable industries: Medical Tech, Advanced engineering, ICT, Creative Industries, and Microelectronics.

Industry benefits include: •To support SMEs in their go to market strategies and for corporate pipeline enrichment. • Exhibitors are guaranteed a speed date with GE Healthcare, Oxford AHSN (NHS) and STFC Researchers and Fund providers such as the MRC, Innovate UK, KTN Finance and Longwall Venture Partners.

23

ATTENDEE LIST

24

Name Last Organisation Event ticketJulie Barnes Abcodia SPEAKERMike Fisher Abcodia VIP DelegatePaul Williams Ablett & Stebbing DelegateBill Johnson Amies Plastics DelegateBelinda Thompson Atlas Genetics DelegateIdo Davids Cellseco Ltd DelegateOliver Blackwell Clever Medical ExhibitorKelie Peters DBX-Data Rockstar DelegateRegina Lally DBX-Data Rockstar VIP DelegatePaul Weinberger Diasolve ExhibitorJustin Dodd Evolve Pro Fitness VIP DelegateGer Brophy GE Healthcare SPEAKER/SPONSORRichard Harvey Hamamatsu Photonics UK ExhibitorWilliam Beckett Hips Protect ExhibitorPenny Wilson InnovateUK SPEAKERDavid Burrows Invest in Oxfordshire DelegateSimon Bayly Invest in Oxfordshire DelegateMark Sage Iseeu Global ExhibitorLee Chapman J A Kemp DelegateBenedicte Thiebaut Johnson Matthey DelegateIan Tracey KTN SPEAKER/SPONSORRichard Foggie KTN VIP DelegateChris Rhoades Leica Microsystems (UK) Ltd VIP DelegateGugs Lushai Life Sciences Healthcare ORGANISERJames Philpott Life Sciences Healthcare ORGANISERDolly Garton Life Sciences Healthcare ORGANISERDavid Denny Longwall Venture Partners SPEAKERPatrick Hall Maddison Product Design Exhibitor

Mark BrincatMcLaren AppliedTechnologies VIP Delegate

Antonia C-Chatzi Medical Research Council DelegateJonathan Pearce Medical Research Council SPEAKERColin Martin Medtech Communications VIP DelegateAndy Morley New Level Health DelegateRuth Nebauer NIHR Central Comm. Facility DelegateJohn Jeans OLS Champion VIP Delegate

Name Last Organisation Event ticket

Nick Scott-Ram Oxford AHSN CHAIR/VIP

Julie Hart Oxford AHSN VIP Delegate

Andrew Gardner Oxford Innovation Network Delegate

Sunil Mistry Pera Technology Delegate

Dan Green Perspectrum Diagnostics Delegate

Keri Hildick Perspectrum Diagnostics Exhibitor

EmmaPalmer-Foster Precision Medical Catapault Delegate

Ronan McGlade Premier Business Media VIP Delegate

Richard A'Court Public Health England Delegate

Neil Burton Q3 Analytical Ltd Delegate

Catherine Philip Quay Tax Delegate

Douglas Findlay Royal Berkshire NHS Trust Delegate

Colin Self Selective Antibodies Exhibitor

Chris Morris STFC VIP Delegate

Sapan Gandhi STFC VIP Delegate

Genoveva Burca STFC VIP Delegate

Adrian Toland STFC VIP Delegate

Mark Burrows STFC VIP Delegate

Izhar Ul-Haq STFC ORGANISER/SPONSOR

Ishea Mbedzi STFC ORGANISER/SPONSOR

Annabel Dominey STFC ORGANISER/SPONSOR

Ian Johnson STFC VIP Delegate

Barbara Camanzi STFC VIP Delegate

Dave Clarke STFC VIP Delegate

Stanley Botchway STFC SPEAKER/SPONSOR

Robert McGreevy STFC HOST/VIP

Alan Letchford STFC SPEAKER/SPONSOR

Angela Hobbs Triteq Delegate

Szabi Steiner UCL IBME VIP Delegate

Stephen Hillier University of Liverpool VIP Delegate

Anthony Young Veale Wasbrough Vizards VIP Delegate

Darren Kell VernaCare VIP Delegate

Nigel Reed Wessex Business Focus Delegate

David Elsy Withers & Rogers Delegate

Joseph Dahhane Zabala Ltd VIP Delegate

LUNCH & EXHIBITION HALL

10

9

1

2

3

45

6

7

8

F

C

1: Hips Protect2: Maddison Product Design3: Perspectrum Diagnostics4: Hamamatsu Photonics UK 5: Clever MedicalC: Refreshments Bar

To Exit

F

6: IseeU Global7: Selective Antibodies8: Diasolve9: STFC (ISIS & CLF)10. LSHF: Food Bar

To Toilets and Exit

25

Exit

Fire Exit

Fire Exit

Novel Markers and Technology for Better Patient Care

EVENT MAP

“R22” Auditorium “Pickavance”

“R68” Exhibition Hall “Space Visitor Centre”

“R75” Reception & Registration

Car Parking

26